Emmanuel J Favaloro/LinkedIn
Aug 21, 2025, 14:55
Emmanuel Favaloro on DOACs Versus Warfarin in the COVID19 Era
“Did the COVID19 pandemic push the use of DOACs to the lead in the ‘anticoagulant race’, and ahead of warfarin?
Well, yes and no.
Depends on where you live. Check out this Commentary in Seminars in Thrombosis and Hemostasis.
Just released online.
Enjoy!”
Stay informed with Hemostasis Today.
-
Apr 19, 2026, 04:47Test Your Hematology Knowledge with ASH Questions and Answers – ASH
-
Apr 19, 2026, 04:26Priyanka Raheja: Happy World Haemophilia Day from The Royal London Haemophilia Centre
-
Apr 18, 2026, 18:55William Aird: Ferritin as a Probability Signal
-
Apr 18, 2026, 18:54Abdulla A. Damluji: OCEANIC-STROKE Trial Analysis and Its Clinical and Market Implications
-
Apr 18, 2026, 18:29Vasee Moorthy: Join WHO Clinical Trial Course Launch at Stand With Science 2026
-
Apr 18, 2026, 18:28Holly O’Byrne: Improving Hemorrhagic Shock Care With a Patient Centered System
-
Apr 18, 2026, 18:26Sthanu Subramanian: CVST as The ‘Great Masquerader’ with Normal Initial CT
-
Apr 18, 2026, 18:25Priyanka Raheja: Sharing the Final Analysis From the Roctavian Phase 1/2 Study
-
Apr 18, 2026, 18:23Jim Hoffman: Reversing Vascular Damage through NETosis Modulation and Efferocytosis Balance